Orion Bliss Corp.

ORIB
About the company

Orion Bliss Corp., a development-stage company that offers beauty products in Israel. The company offers milk shake hairline products; beauty consulting services; and beauty care training programs. It also provides its products through online. Orion Bliss Corp. was incorporated in 2021 and is based in Ashdod, Israel.

Country: United StatesPrice: $13.20Market Cap: $40.1M

Investment snapshot

0%positive consensus
Scored 1d ago

Positive

0

BUY / PASS

Neutral / negative

2 / 14

NEUTRAL / FAIL

Median fair value

—

No comparable estimates

Models with upside

0 / 17

Positive margin of safety

Key risk

All 13 investors flag ORIB's valuation

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Greenblatt

Magic Formula

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictFAILFAILFAILNot rankedFAILFAILFAILFAILFAILFAILFAILFAILFAILNEUTRALFAILFAILNEUTRAL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Margin of SafetyN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Financial Basis

TTM ended 2026-07-31 · Balance sheet at 2026-07-31 · Annual history · FY 2025

Latest source filing: 2026-08-25

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-07-08

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-07-31 · TTM ended 2026-07-31

Latest source filing: 2026-08-25

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-07-08

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-07-08

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-07-31 · Balance sheet at 2026-07-31 · Market data at 2026-11-01

Latest source filing: 2026-08-25

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025 · TTM ended 2026-07-31 · Balance sheet at 2026-07-31

Latest source filing: 2026-08-25

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-07-08

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment · Balance sheet at 2026-07-31

Latest source filing: 2026-08-25

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-07-08

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-07-31 · Balance sheet at 2026-07-31 · Market data at 2026-11-01

Latest source filing: 2026-08-25

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2026-02-01–2026-11-01 · Balance sheet at 2026-07-31

Latest source filing: 2026-08-25

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-07-08

Score computed: 2026-11-14

TTM ended 2026-07-31 · Balance sheet at 2026-07-31 · Price history 2026-02-01–2026-11-01 · Annual history · FY 2025

Latest source filing: 2026-08-25

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-07-08

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-07-31

Latest source filing: 2026-08-25

Score computed: 2026-11-14

TTM ended 2026-07-31 · Annual history · FY 2025 · Price history 2026-02-01–2026-11-01

Latest source filing: 2026-08-25

Score computed: 2026-11-14

Where It Passes

    Where It Falls Short

    • Valuation0% pass✗ 28▾

      All 13 investors flag ORIB's valuation

      Price / 3-yr avg EPS
      ✗Graham<= 15x
      Price-to-Book Ratio
      ✗Graham<= 1.5x
      P/E x P/B
      ✗Graham<= 22.5
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      EBIT / Enterprise Value-0.1%
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=-0.1%, ROC=None
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Price / EPS
      ✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
      Price / (CFO / Shares)N/A (negative CFPS)
      ✗Dreman< 8x
      Price / Book Value per ShareN/A (negative BVPS)
      ✗Dreman< 1.2x✗Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)
      Valuation Reasonableness
      ✗MungerP/E < 25 or Owner Earnings Yield > 5%
      P/E or FCF Yield
      ✗PabraiP/E < 15 or FCF Yield > 10%
      P/B or P/E vs. Historical Average
      ✗MarksP/E < 15 or P/B < 2.0
      Discount to Intrinsic ValueN/A (negative normalized EPS)
      ✗Marks>= 20% below intrinsic value
      Price / FCF per Share
      ✗Ackman<= 25
      Price vs. Trailing Low
      ✗Templeton<= 120% of trailing low (certified split-adjusted live window)
      Net income / market capitalization-0.08%; #3222/6340 (top 50.8%)
      ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
      Positive book equity / market capitalization-0.0037; #5298/6449 (top 82.2%)
      ✗AsnessTop 30% of eligible cross-section
      Price / Diluted EPS
      ✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
      (EPS CAGR % + Dividend Yield %) / P/E
      ✗Neff> 0.7 (Neff's published traditional edge)
      Price / Tangible Book Value per ShareN/A (non-positive TBVPS)
      ✗SchlossP/TBV <= 1.00x (app cutoff)
      Book Value per Share Change
      ✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
      Revenue / market capitalization+0.0005; #5037/5247 (top 96.0%)
      ✗OshaughnessyTop 10% of eligible cross-section
      (Operating cash flow - capex) / market capitalization
      ✗OshaughnessyTop 10% of eligible cross-section
      Trailing six-month price return through the evaluation date
      ✗OshaughnessyTop 10% of eligible cross-section
    • Cash Flow0% pass✓ 1✗ 11▾

      No clean pass — all 10 investors flag at least one cash flow criterion

      Free Cash Flow Proxy
      ✗BuffettPositive and growing
      FCF Positive and Growing
      ✗LynchPositive and growing
      Operating Cash Flow$-0.0M
      ✗PiotroskiCFO > 0
      (CFO / Total Assets) vs ROACFO/Assets=-85.96%, ROA=-110.54%
      ✓PiotroskiCFO/Assets > ROA
      Price / (CFO / Shares)N/A (negative CFPS)
      ✗Dreman< 8x
      P/E or FCF Yield
      ✗PabraiP/E < 15 or FCF Yield > 10%
      FCF Positive
      ✗MarksPositive FCF in majority of recent years
      (OCF - CapEx) / Market Cap
      ✗Ackman>= 4%
      Price / FCF per Share
      ✗Ackman<= 25
      Positive Operating Cash Flow frequency0/5 years positive
      ✗SleepPositive OCF in >= 70% of available years
      Operating Cash Flow - Capital Expenditures
      ✗Neff> $0 (app proxy for a strong fundamental case)
      (Operating cash flow - capex) / market capitalization
      ✗OshaughnessyTop 10% of eligible cross-section
    • Growth0% pass✓ 2✗ 11▾

      No clean pass — all 8 investors flag at least one growth criterion

      EPS Growth (3-yr avg, 10-yr window)N/A (negative base EPS)
      ✗Graham>= 33% growth
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      Inventory Growth vs Revenue GrowthN/A (no inventory)
      ✓LynchInventory growth < Revenue growth
      EPS Growth Direction$0.00 (2021) -> $0.00 (2025)
      ✗DremanPositive over recent years
      EPS CAGR
      ✗Dreman> 5% annualized
      Positive Net Income Frequency0/5 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      3yr Median Revenue Growth-16.7%
      ✗Ackman>= 5%
      Positive EPS Growth Frequency0/4 years with positive EPS growth
      ✗AckmanPositive EPS growth in >= 3 of last 5 years
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Revenue growth vs. gross and operating margin trendrevenue up, operating margin -10471.2% -> -341.1%
      ✓SleepRevenue rising; gross margin flat or falling; operating margin holding
      5-year Revenue CAGR
      ✗SleepCAGR > 7%
      3-5 Year Diluted EPS CAGR
      ✗Neff7%-20% annualized
    • Efficiency0% pass✗ 11▾

      All 8 investors flag ORIB's efficiency

      Current Ratio0.04
      ✗Graham>= 2.0
      ROIC (3-5 yr avg)
      ✗Buffett> 10%
      ROIC - WACC
      ✗BuffettPositive (WACC = 10%)
      EBIT / (NWC + Net Fixed Assets)
      ✗Greenblatt> 25%
      Current Ratio Change YoY0.12 -> 0.03
      ✗PiotroskiIncreased YoY
      Revenue / Total Assets Change YoY0.43x -> 0.32x
      ✗PiotroskiImproved YoY
      Current Assets / Current Liabilities0.04
      ✗Dreman> 1.5
      Return on Invested CapitalN/A (non-positive invested capital)
      ✗Munger> 15%
      ROIC (high and growing)FY2023: ROIC=unavailable; FY2024: ROIC=unavailable; FY2025: ROIC=unavailable
      ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
      Reinvestment Rate x ROIC
      ✗AkreReinvestment Rate * ROIC > 10%
      ROIC (5-year)
      ✗SleepROIC > 12% in a majority of years
    • Verdicts0% pass✗ 14▾

      Split decision: 14 FAIL · 2 NEUTRAL

      Overall verdict
      ✗GrahamFAIL (0/9)✗BuffettFAIL (1/9)✗LynchFAIL (1/7)•GreenblattNot ranked✗PiotroskiFAIL (F-Score 3)✗DremanFAIL (0/11)✗MungerFAIL (0/4)✗PabraiFAIL (0/3)✗AkreFAIL (0/6)✗MarksFAIL (0/5)✗AckmanFAIL (0/9)✗TempletonFAIL (2/8)✗SleepFAIL (2/6)•AsnessNEUTRAL (Not ranked)✗NeffFAIL (1/6)✗SchlossFAIL (0/7)•OshaughnessyNEUTRAL (Not ranked)
    • Profitability6% pass✓ 4✗ 31▾

      15 of 16 flag ORIB's profitability — Graham, Buffett, Lynch +12 more

      Positive EPS (10 years)0/6 years positive
      ✗GrahamPositive EPS every year for 10 years
      EPS Growth (3-yr avg, 10-yr window)N/A (negative base EPS)
      ✗Graham>= 33% growth
      Net Income Positive (10+ years)0/6 years positive
      ✗BuffettPositive every year for 10+ years
      ROE (up to 5-year arithmetic mean)
      ✗Buffett> 15% arithmetic mean (app rule)
      Operating Margin (10-yr trend)-341.1% (latest)
      ✓BuffettStable or rising over 10 years
      Free Cash Flow Proxy
      ✗BuffettPositive and growing
      Earnings Variance (10-yr CoV)N/A (negative mean EPS)
      ✗BuffettCoV < 0.3
      Retained Earnings Effectiveness
      ✗Buffett$1 retained -> > $1 market value created
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      ROEN/A (negative equity)
      ✗Lynch> 15%
      EBIT / Enterprise Value-0.1%
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=-0.1%, ROC=None
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Net Income / Total Assets-110.54%
      ✗PiotroskiROA > 0
      ROA Change YoY-24.26% -> -110.54% (delta: -86.28%)
      ✗PiotroskiCurrent ROA > Prior ROA
      (CFO / Total Assets) vs ROACFO/Assets=-85.96%, ROA=-110.54%
      ✓PiotroskiCFO/Assets > ROA
      Gross Margin Change YoY
      ✗PiotroskiImproved YoY
      Pre-Tax Income / Revenue
      ✗Dreman>= 8%
      Net Income / Shareholders' Equity
      ✗Dreman> 12%
      Margin of Safety
      ✗PabraiP/B < 1.5 or P/E < 15
      Return on Equity
      ✗AkreROE > 20% (3-year avg)
      Discount to Intrinsic ValueN/A (negative normalized EPS)
      ✗Marks>= 20% below intrinsic value
      Positive Net Income Frequency0/5 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      Operating Income / Revenue-158.3%
      ✗Ackman>= 15%
      Net Income / Shareholders Equity
      ✗Ackman>= 15%
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Operating Margin Trend-10471.2% (2023) -> -341.1% (2025)
      ✓TempletonNon-negative operating-margin trend over 3 years
      Revenue growth vs. gross and operating margin trendrevenue up, operating margin -10471.2% -> -341.1%
      ✓SleepRevenue rising; gross margin flat or falling; operating margin holding
      Net income / market capitalization-0.08%; #3222/6340 (top 50.8%)
      ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
      Gross profit / total assets
      ✗AsnessTop 30% of eligible cross-section
      Net income / positive book equity
      ✗AsnessTop 30% of eligible cross-section
      Negative 5-year standard deviation of ROA-18.3268; #5740/5884 (top 97.6%)
      ✗AsnessTop 30% of eligible cross-section
      3-5 Year Diluted EPS CAGR
      ✗Neff7%-20% annualized
      Positive Diluted-EPS Years0/5 years positive
      ✗Schloss>= 70% positive over 5-10 observed years (app rule)
    • Debt & Leverage8% pass✓ 1✗ 14▾

      11 of 12 flag ORIB's debt & leverage — Graham, Buffett, Lynch +8 more

      LT Debt vs Net Current Assets
      ✗GrahamLT Debt <= Net Current Assets
      Debt/Equity & Interest CoverageD/E: N/A (negative equity), IC: N/A
      ✗BuffettD/E < 0.5 AND Interest Coverage > 5x
      Total Debt / EquityN/A (negative equity)
      ✗Lynch< 0.33
      Cash - Long-term Debt
      ✗LynchPositive preferred
      LT Debt / Total Assets Change0.00% -> 0.00%
      ✓PiotroskiDecreased YoY
      Current Assets / Current Liabilities0.04
      ✗Dreman> 1.5✗SchlossCurrent ratio >= 1.50x (app cutoff)
      Total Debt / Shareholders' Equity
      ✗Dreman< 0.8✗Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✗SchlossD/E < 1.00x
      Debt LevelsN/A (non-positive equity)
      ✗MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3
      Interest Coverage & Debt/EBITDA
      ✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x
      Total Debt / Shareholders Equity
      ✗Ackman<= 1.0
      Negative debt-to-equity (higher means less debt)
      ✗AsnessTop 30% of eligible cross-section

    Business & financials

    Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.

    Company Profile

    Industry: Consumer Goods
    SIC Sector: Chemicals & Pharmaceuticals
    Size: Micro Cap($40.1M)
    Revenue: $12000.00-53.9% YoY
    Net Income: $-40926.00-178.4% YoY

    Financial Snapshot

    Operating Margin-341.1%
    Return on Equity28.3%
    Debt / Equity-0.31
    Current Ratio0.03
    EPS (Diluted)$0.00
    Shares Retired0.0% / 0.0% 2y

    Shareholder Return

    Fiscal 2025

    Retired 0.0% of shares last year, 0.0% over two.

    Buybacks
    —
    Dividends
    —

    Company Financials

    Latest TTM and quarters alongside annual years

    TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

    The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.

    MetricTTM · 2026-07-31

    2025-08-01 – 2026-07-31

    Sources · derived quarter values

    Derived from cumulative filings: operating cash flow, revenue, net income, operating income, ebit.

    Q1 FY 2027

    2026-05-01 – 2026-07-31

    Sources
    FY 2025
    Sources
    • 10-K · 2026-07-08
    FY 2024
    Sources
    • 10-K · 2025-07-08
    FY 2023
    Sources
    • 10-K · 2025-07-08
    FY 2022
    Sources
    • 10-K · 2024-06-04
    FY 2021
    Sources
    • 10-K/A · 2022-06-29
    Market Cap$40.1Mcurrent--$3.8Mest.--------
    Revenue$21.0K↓28%$12.0K↑300%$12.0K↓54%$26.0K↑5103%$500↓17%$600$0
    Operating Income-$33.2K↓161%-$3.8K↑67%-$40.9K↓178%-$14.7K↑72%-$52.4K↓79%-$29.2K↓9%-$26.7K
    Net Income-$33.2K↓161%-$3.8K↑67%-$40.9K↓178%-$14.7K↑72%-$52.4K↓79%-$29.2K↓9%-$26.7K
    EPS (Diluted)--$0.00$0.00$0.00$0.00$0.00$0.00
    Gross Margin———————
    Operating Margin-158.3%↓261%-32.0%↑92%-341.1%↓503%-56.5%↑99%-10471.2%↓115%-4863.7%—
    ROE22.4%↑103%—28.3%↑100%14.2%↓76%58.7%↓26%79.2%↓16%93.9%
    Total Debt$45.5K$45.5K$45.5K$45.5K------
    Shareholders' Equity-$148.7K↓29%-$148.7K↓29%-$144.8K↓39%-$103.9K↓16%-$89.2K↓142%-$36.8K↓30%-$28.4K
    Current Ratio0.04↓52%0.04↓52%0.03↓77%0.12↑803%0.01↓93%0.18↑3668%0.00
    Debt / Equity-0.31↑22%-0.31↑22%-0.31↑28%-0.44———
    Operating Cash Flow-$27.1K↓838%-$1.6K↑75%-$31.8K↓213%-$10.2K↑81%-$52.4K↓79%-$29.2K↓9%-$26.8K
    Free Cash Flow--------------

    Score history

    Historical Score Timeline

    Industry peers

    Industry Peers

    Similar companies in Consumer Goods

    ORIB vs Peers — Financial Grading

    Revenue$12000.00Bottom 25%
    Net Income$-40926.00Bottom 25%
    ROE28.3%Median
    D/E-0.31Top 25%
    Op. Margin-341.1%Bottom 25%
    Curr. Ratio0.03Bottom 25%
    CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchGreenblattPiotroskiDreman
    UNILEVER PLCUL$142.6B$66.21$59.3B$11.1B61.0%1.6817.9%0.792/94/94/71/3F-Score 86/11
    ECOLAB INC.ECL$86.7B$309.27$16.1B$2.1B21.2%0.8417.0%1.083/95/93/71/3F-Score 65/11
    COLGATE PALMOLIVE COCL$79.2B$99.67$20.4B$2.1B3948.1%147.8916.2%0.832/95/93/71/3F-Score 53/11
    ESTEE LAUDER COMPANIES INCEL$40.5B$111.75$14.3B$1.1B-29.3%1.89-5.5%1.302/94/92/70/3F-Score 61/11
    CHURCH & DWIGHT CO INC /DE/CHD$26.7B$113.00$6.2B$736.8M18.4%0.5517.4%1.073/97/93/71/3F-Score 74/11
    CANON INCCAJPY$25.2B$30.28——————3/91/91/71/3F-Score 75/11
    SOMNIGROUP INTERNATIONAL INC.SGI$14.0B$60.76$7.5B$384.1M12.4%1.5110.1%0.831/95/92/71/3F-Score 52/11
    INTERPARFUMS INCIPAR$4.3B$133.37$1.5B$168.4M19.1%0.2018.2%2.994/95/96/71/3F-Score 57/11